<DOC>
	<DOCNO>NCT02759406</DOCNO>
	<brief_summary>This six ( 6 ) month , randomize , un-blinded , study assess safety performance Palmaz Mach-5 Grooved Coronary Stent System vs. Palmaz Bare Metal Coronary Stent System .</brief_summary>
	<brief_title>Evaluation Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus Palmaz Bare Metal Coronary Stent System Patients With Symptomatic Ischemic Heart Disease : A Safety Performance Study</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Male female patient race great equal 18 year legal consent 2 . Patients must willing comply specify followup evaluation schedule 3 . Patients sign inform consent ( sign date ) prior studyrelated evaluation procedure . 4 . Patients willing undergo followup coronary angiogram Endovascular Imaging via Optical Coherence Tomography 5 . Patients willing maintain Aspirin Clopidogrel bisulfate ( Plavix ) ninety ( 90 ) day post procedure . 6 . Patients de novo coronary lesion cause angina and/or positive function test 7 . Patients eligible percutaneous coronary intervention 8 . Low risk NSTEMI define patient ACS , unstable angina , positive cardiac biomarkers hemodynamically stable assessed Investigator . 9 . Patients acceptable risk coronary bypass graft surgery ( CABG ) IntraProcedure Angiographic Criteria : 1 . Single de novo target lesion &gt; 50 % diameter stenosis angiography 2 . Single target vessel 2.75 3.25 mm diameter 3 . Lesion length 14 20mm suitable Palmaz Mach5 Grooved Coronary Stent System Palmaz Bare Metal Coronary Stent System . 1 . Known allergy sensitivity cobalt chromium ( CoCr ) alloy component . 2 . Known sensitivity allergy aspirin , radiographic contract agent ( pretreated adequately ) . 3 . Patients unable tolerate anticoagulant therapy antiplatelet therapy . 4 . History bleed know coagulopathy . 5 . Patients thrombocytopenia neutropenia . 6 . More one stenosis &gt; 50 % target vessel . 7 . Lesion aortic ostium . 8 . Left main LAD , CX lesion within 2mm origin . 9 . Ejection Fraction &lt; 45 % . 10 . STEMI evolution . 11 . Disabling stroke within previous 30 day . 12 . Patients currently enrol another Investigational device drug study . 13 . Previous enrollment study . 14 . Women currently pregnant . ( A negative pregnancy test female subject child bear potential require within 24 hour procedure . ) 15 . Known suspect active systemic infection . 16 . Evidence severe uncontrolled systemic disease , include chronic renal insufficiency , condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>